Clovis Oncology shares jumped more than 15 percent after the FDA opted to not hold an advisory committee meeting to discuss the company’s application for its ovarian cancer drug rucaparib.
Retrophin Inc. said its drug to treat a rare kidney disorder was found effective in a mid-stage study.
Tonix Pharmaceuticals Holding Corp. said it would stop developing its drug for fibromyalgia after the treatment failed in a late-stage trial.
Novo Nordisk’s chief executive Lars Rebien Sorensen is to step down at a time when the world’s largest insulin maker has said it faces increased U.S. competition.
Rigel Pharmaceuticals Inc. said its experimental drug to treat a bleeding disorder met its main goal in the first of two late-stage trials.
Drugmaker Vectura Group Plc said its asthma therapy Flutiform had not met the primary endpoint in a late-stage trial to determine its ability to treat COPD.
Valeant Pharmaceuticals International Inc. was sued by buyers of its drugs, who accused the Canadian company of racketeering by forcing them to pay exorbitant prices.
Pharmaceutical company AstraZeneca has agreed to sell its small molecule antibiotics business to Pfizer Inc. in a deal that could be valued at more than $1.5 billion.
Pfizer Inc. – beating out numerous other bidders – said it would buy U.S. cancer drug company Medivation Inc. for $14 billion in cash.
The U.S. Food and Drug Administration has widened the use of Edwards Lifesciences’ heart valves to patients at intermediate risk of complications if they underwent open heart surgery.